I am currently working on a project with our lung cancer research group at Rush University Medical Center in Chicago in which we are looking at expression of the BCL-2 family protein, MCL-1. MCL-1 is interesting because it can either be anti- or pro-apoptotic depending on alternative splicing. So I was interested in this nice review article that explores the role of novel targeted agents in SCLC. This article specifically discusses agents targeting the bcl-2 protein family. The prognosis for SCLC remains pretty dismal but there is a lot of interest in this malignancy because of the better understanding of pathways involved in SCLC and the development of "targeted" therapies.
Hurwitz J, McCoy F, Scullin P, Fennell D. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986-994.